What we cannot miss in clinical trials on compression therapy.

IF 1.5
Giovanni Mosti, Serge Bohbot, Christine Bongards, J P Benigni, Nele Devoogdt, Isabel Forner-Cordero, Sergio Gianesini, Ravul Jindal, Fedor Lurie, Eduardo da Matta, Makoto Mo, Didier Rastel, Claas Roes, Wassila Taha, Sarah Thomis, Cees Wittens
{"title":"What we cannot miss in clinical trials on compression therapy.","authors":"Giovanni Mosti, Serge Bohbot, Christine Bongards, J P Benigni, Nele Devoogdt, Isabel Forner-Cordero, Sergio Gianesini, Ravul Jindal, Fedor Lurie, Eduardo da Matta, Makoto Mo, Didier Rastel, Claas Roes, Wassila Taha, Sarah Thomis, Cees Wittens","doi":"10.1177/02683555251377228","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundCompression therapy (CT) is widely prescribed for chronic venous disease (CVD), lymphedema, and lipedema despite robust evidence supporting its effectiveness only in a minority of clinical scenarios.AimProvide an overview of the methodological parameters essential for obtaining a high-quality scientific trial.MethodsThe International Compression Club (ICC) chairman prepared a preliminary list of the main methodological flaws in publications on CT, and a list of parameters to be included in high-quality randomized controlled trials (RCTs). This list was circulated among ICC board members, who provided their comments and suggestions. The document was then presented and discussed at an ICC consensus meeting with various professionals in May 2024 in London. Meeting minutes were distributed to ICC members, and the final document reflecting all additional comments and suggestions was compiled. In summary, the following recommendations represent the consensus of the ICC members.ResultsThe ICC recommends that the following parameters be reported in randomized clinical trials (RCTs): appropriate patient selection, adequate sample size, detailed classification of venous and lymphatic diseases, detailed description of CT modality, adherence to CT, and reasons for non-adherence. Tailored recommendations for specific scenarios and the use of standardized quality-of-life (QoL) tools are emphasized. Despite their value, RCTs face limitations and do not reflect real-world clinical practice. Real-world evidence (RWE) can complement RCTs by providing insights into routine applications, safety, compliance, and cost-effectiveness across diverse patient populations by standardized methodologies, large cohorts, and reliable validated registries to ensure validity.ConclusionsCombining data from RCTs and RWS allows for a comprehensive understanding of CT. RCTs provide evidence of effectiveness in a controlled scenario, while RWE offers real-world perspectives on compliance and economic outcomes in clinical practice. Together, these approaches enable a more holistic evaluation of CT, addressing current gaps in knowledge and guiding its optimal use.</p>","PeriodicalId":94350,"journal":{"name":"Phlebology","volume":" ","pages":"2683555251377228"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02683555251377228","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundCompression therapy (CT) is widely prescribed for chronic venous disease (CVD), lymphedema, and lipedema despite robust evidence supporting its effectiveness only in a minority of clinical scenarios.AimProvide an overview of the methodological parameters essential for obtaining a high-quality scientific trial.MethodsThe International Compression Club (ICC) chairman prepared a preliminary list of the main methodological flaws in publications on CT, and a list of parameters to be included in high-quality randomized controlled trials (RCTs). This list was circulated among ICC board members, who provided their comments and suggestions. The document was then presented and discussed at an ICC consensus meeting with various professionals in May 2024 in London. Meeting minutes were distributed to ICC members, and the final document reflecting all additional comments and suggestions was compiled. In summary, the following recommendations represent the consensus of the ICC members.ResultsThe ICC recommends that the following parameters be reported in randomized clinical trials (RCTs): appropriate patient selection, adequate sample size, detailed classification of venous and lymphatic diseases, detailed description of CT modality, adherence to CT, and reasons for non-adherence. Tailored recommendations for specific scenarios and the use of standardized quality-of-life (QoL) tools are emphasized. Despite their value, RCTs face limitations and do not reflect real-world clinical practice. Real-world evidence (RWE) can complement RCTs by providing insights into routine applications, safety, compliance, and cost-effectiveness across diverse patient populations by standardized methodologies, large cohorts, and reliable validated registries to ensure validity.ConclusionsCombining data from RCTs and RWS allows for a comprehensive understanding of CT. RCTs provide evidence of effectiveness in a controlled scenario, while RWE offers real-world perspectives on compliance and economic outcomes in clinical practice. Together, these approaches enable a more holistic evaluation of CT, addressing current gaps in knowledge and guiding its optimal use.

我们在临床试验中不能错过的是压迫疗法。
背景:压缩疗法(CT)被广泛用于慢性静脉疾病(CVD)、淋巴水肿和脂质水肿,尽管有强有力的证据支持其仅在少数临床情况下有效。目的概述获得高质量科学试验所必需的方法学参数。方法国际压缩俱乐部(International Compression Club, ICC)主席准备了一份CT出版物中主要方法学缺陷的初步清单,以及一份用于高质量随机对照试验(RCTs)的参数清单。这份清单在国际商会董事会成员之间分发,他们提出了意见和建议。该文件随后于2024年5月在伦敦举行的国际商会共识会议上与各专业人士进行了讨论。会议纪要分发给国际商会成员,并汇编了反映所有补充意见和建议的最后文件。总之,以下建议代表了国际商会成员的共识。ICC建议在随机临床试验(RCTs)中报告以下参数:适当的患者选择,足够的样本量,静脉和淋巴疾病的详细分类,CT模式的详细描述,坚持CT和不坚持的原因。强调针对特定场景的量身定制的建议和标准化生活质量(QoL)工具的使用。尽管有其价值,但随机对照试验面临局限性,不能反映现实世界的临床实践。真实世界证据(RWE)可以补充随机对照试验,通过标准化的方法、大型队列和可靠的验证注册来提供对不同患者群体的常规应用、安全性、合规性和成本效益的见解,以确保有效性。结论结合rct和RWS的数据可以全面了解CT。随机对照试验提供了受控情况下有效性的证据,而RWE提供了临床实践中依从性和经济结果的现实世界视角。总之,这些方法能够对连续油管进行更全面的评估,解决目前的知识空白,并指导其最佳使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信